Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Core Viewpoint - Psyence Biomedical Ltd. is advancing its strategic relationship with Psyence Labs Ltd. through the exercise of a put option agreement, which involves an equity investment in PsyLabs to enhance its supply strategy for pharmaceutical-grade psychedelic compounds [1][3][7]. Transaction Overview - Psyence BioMed will acquire equity securities of PsyLabs at a fair market value, with the investment expected to strengthen the strategic alignment between the two companies [3][4]. - The Share-for-Share Exchange will involve PsyLabs issuing 2,900 shares valued at US$5,000,000, while Psyence BioMed will issue 1,146,159 common shares based on a 30-day VWAP of US$4.36 per share [5][6]. - No cash will be exchanged in this transaction, and following the issuance of shares, PsyLabs will own approximately 49.98% of Psyence BioMed's outstanding common shares [6][5]. Strategic Context - The exercise of the put option is seen as a step towards securing high-quality manufacturing capabilities while maintaining capital allocation discipline as Psyence BioMed's development programs progress [7]. Governance - A Special Committee of independent directors reviewed and ratified the transaction, considering the commercial rationale and an independent valuation of PsyLabs [8]. About PsyLabs - PsyLabs is a federally licensed company specializing in the development of psychedelic Active Pharmaceutical Ingredients (APIs), including psilocybin and ibogaine, and has successfully exported products to various countries [9][10]. - The company operates from an ISO 22000-certified facility, ensuring high safety and traceability standards [11]. About Psyence BioMed - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psychedelic therapeutics, specifically psilocybin and ibogaine, to address unmet mental health needs [11].